Celgene (NASDAQ:CELG) has been assigned a $127.00 price objective by research analysts at SunTrust Banks in a report issued on Sunday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. SunTrust Banks’ target price suggests a potential upside of 21.69% from the company’s current price.
A number of other research firms have also weighed in on CELG. Royal Bank of Canada reaffirmed a “buy” rating and set a $173.00 price objective on shares of Celgene in a research report on Thursday, October 5th. Morgan Stanley lowered Celgene from an “equal weight” rating to an “underweight” rating and set a $120.00 price objective for the company. in a research report on Thursday, October 5th. Robert W. Baird reaffirmed a “buy” rating and set a $162.00 price objective on shares of Celgene in a research report on Thursday, September 21st. Cantor Fitzgerald reiterated a “buy” rating and set a $162.00 target price on shares of Celgene in a research note on Tuesday, September 26th. Finally, Jefferies Group reiterated a “buy” rating and set a $160.00 target price on shares of Celgene in a research note on Friday, September 15th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, twenty have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $132.63.
Celgene (NASDAQ:CELG) opened at $104.36 on Friday. Celgene has a 52-week low of $94.55 and a 52-week high of $147.17. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. The firm has a market capitalization of $82,164.40, a P/E ratio of 24.79, a P/E/G ratio of 0.81 and a beta of 1.77.
A number of institutional investors have recently made changes to their positions in CELG. Atlantic Trust Group LLC raised its holdings in Celgene by 216.2% during the third quarter. Atlantic Trust Group LLC now owns 900,053 shares of the biopharmaceutical company’s stock valued at $131,246,000 after acquiring an additional 615,366 shares during the period. Chicago Partners Investment Group LLC raised its holdings in Celgene by 756.7% during the third quarter. Chicago Partners Investment Group LLC now owns 6,631 shares of the biopharmaceutical company’s stock valued at $967,000 after acquiring an additional 5,857 shares during the period. Steward Partners Investment Advisory LLC bought a new stake in Celgene during the third quarter valued at about $3,149,000. Public Employees Retirement System of Ohio raised its holdings in Celgene by 1.9% during the third quarter. Public Employees Retirement System of Ohio now owns 601,520 shares of the biopharmaceutical company’s stock valued at $87,714,000 after acquiring an additional 11,416 shares during the period. Finally, GSA Capital Partners LLP bought a new stake in Celgene during the third quarter valued at about $1,370,000. 79.74% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: “Celgene (CELG) Given a $127.00 Price Target by SunTrust Banks Analysts” was reported by American Banking and Market News and is owned by of American Banking and Market News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/01/celgene-celg-given-a-127-00-price-target-by-suntrust-banks-analysts.html.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
